id	sid	eid	entity	type
dpc-5933	2	1	2025;15(4):5933 1	CARDINAL
dpc-5933	2	2	korean	NORP
dpc-5933	2	3	48-week	DATE
dpc-5933	2	4	nguyen1,2	ORDINAL
dpc-5933	2	5	lee1	PERSON
dpc-5933	2	6	ham1	PERSON
dpc-5933	2	7	ju hee lee1,3	PERSON
dpc-5933	2	8	yonsei university college of medicine	ORG
dpc-5933	2	9	seoul	GPE
dpc-5933	2	10	republic of	ORG
dpc-5933	2	11	korea 2	ORG
dpc-5933	2	12	ho chi minh city	GPE
dpc-5933	2	13	ho chi minh city	GPE
dpc-5933	2	14	vietnam	GPE
dpc-5933	2	15	3	CARDINAL
dpc-5933	2	16	seoul	GPE
dpc-5933	2	17	republic of korea	ORG
dpc-5933	3	1	secukinumab	PERSON
dpc-5933	4	1	secukinumab	GPE
dpc-5933	4	2	korean	NORP
dpc-5933	4	3	nguyen nh	PERSON
dpc-5933	4	4	lee sg	PERSON
dpc-5933	4	5	lee jh	PERSON
dpc-5933	4	6	lee yi	PERSON
dpc-5933	5	1	secukinumab	PERSON
dpc-5933	5	2	korean	NORP
dpc-5933	5	3	48-week	DATE
dpc-5933	7	1	2025;15(4):5933	CARDINAL
dpc-5933	8	1	june 2, 2025	DATE
dpc-5933	9	1	october 2025	DATE
dpc-5933	9	2	2025	CARDINAL
dpc-5933	9	3	nguyen et al	PERSON
dpc-5933	10	1	https://creativecommons.org/licenses/by-nc/4.0/	ORG
dpc-5933	14	1	lee	GPE
dpc-5933	14	2	m.d.	GPE
dpc-5933	14	3	ph.d	ORG
dpc-5933	15	1	yonsei university college of medicine	ORG
dpc-5933	15	2	seoul	GPE
dpc-5933	15	3	korea	GPE
dpc-5933	15	4	50	DATE
dpc-5933	15	5	yonsei-ro	PERSON
dpc-5933	15	6	korea	GPE
dpc-5933	19	1	il-17a	PRODUCT
dpc-5933	19	2	secukinumab	GPE
dpc-5933	21	1	48-week	DATE
dpc-5933	21	2	10	CARDINAL
dpc-5933	21	3	korean	NORP
dpc-5933	22	1	weeks 0	DATE
dpc-5933	22	2	1	DATE
dpc-5933	22	3	2	DATE
dpc-5933	22	4	3	DATE
dpc-5933	22	5	4	DATE
dpc-5933	22	6	every two weeks	DATE
dpc-5933	23	1	55%	PERCENT
dpc-5933	23	2	30%	PERCENT
dpc-5933	24	1	week 48	DATE
dpc-5933	24	2	90%	PERCENT
dpc-5933	24	3	90%	PERCENT
dpc-5933	24	4	60%	PERCENT
dpc-5933	25	1	hurley stage ii	PERSON
dpc-5933	25	2	10 years	DATE
dpc-5933	25	3	week	DATE
dpc-5933	25	4	2	CARDINAL
dpc-5933	26	1	2025;15(4):5933	CARDINAL
dpc-5933	27	1	1	CARDINAL
dpc-5933	30	1	2	CARDINAL
dpc-5933	31	1	3	CARDINAL
dpc-5933	33	1	interleukin-17	DATE
dpc-5933	33	2	4	CARDINAL
dpc-5933	35	1	adalimumab	PERSON
dpc-5933	35	2	fda	ORG
dpc-5933	35	3	hs	ORG
dpc-5933	35	4	2015	DATE
dpc-5933	35	5	5	CARDINAL
dpc-5933	36	1	6-8	CARDINAL
dpc-5933	37	1	two	CARDINAL
dpc-5933	37	2	9	CARDINAL
dpc-5933	38	1	42–45%	PERCENT
dpc-5933	38	2	16 weeks	DATE
dpc-5933	38	3	52 weeks	DATE
dpc-5933	39	1	9	CARDINAL
dpc-5933	40	1	10	CARDINAL
dpc-5933	40	2	fda	ORG
dpc-5933	40	3	31	CARDINAL
dpc-5933	40	4	2023	CARDINAL
dpc-5933	42	1	hs	PERSON
dpc-5933	43	1	48-week	DATE
dpc-5933	43	2	korean	NORP
dpc-5933	43	3	secukinumab	GPE
dpc-5933	43	4	korean	NORP
dpc-5933	43	5	48-week	DATE
dpc-5933	45	1	seoul	GPE
dpc-5933	45	2	korea	GPE
dpc-5933	45	3	may 2023 to november 2024	DATE
dpc-5933	46	1	novartis	ORG
dpc-5933	48	1	18 years old	DATE
dpc-5933	48	2	over six months	DATE
dpc-5933	48	3	five	CARDINAL
dpc-5933	48	4	two	CARDINAL
dpc-5933	50	1	300 mg	QUANTITY
dpc-5933	50	2	secukinumab	GPE
dpc-5933	50	3	weeks 48	DATE
dpc-5933	52	1	secukinumab	PERSON
dpc-5933	57	1	2025;15(4):5933	CARDINAL
dpc-5933	57	2	0	CARDINAL
dpc-5933	57	3	1	DATE
dpc-5933	57	4	2	DATE
dpc-5933	57	5	3	DATE
dpc-5933	57	6	4	DATE
dpc-5933	57	7	every two weeks	DATE
dpc-5933	57	8	48 weeks	DATE
dpc-5933	58	1	ta ili	PERSON
dpc-5933	58	2	i&d	GPE
dpc-5933	59	1	10 years	DATE
dpc-5933	60	1	larger than	QUANTITY
dpc-5933	60	2	10 mm	QUANTITY
dpc-5933	61	1	three	CARDINAL
dpc-5933	61	2	10 mm	QUANTITY
dpc-5933	63	1	9	CARDINAL
dpc-5933	64	1	one	CARDINAL
dpc-5933	64	2	17	CARDINAL
dpc-5933	65	1	the previous 24 hours	TIME
dpc-5933	65	2	0	CARDINAL
dpc-5933	65	3	10	CARDINAL
dpc-5933	66	1	weeks 4, 8,	DATE
dpc-5933	66	2	16	DATE
dpc-5933	66	3	32	DATE
dpc-5933	66	4	48	DATE
dpc-5933	67	1	•	CARDINAL
dpc-5933	67	2	50%	PERCENT
dpc-5933	67	3	18	CARDINAL
dpc-5933	68	1	•	CARDINAL
dpc-5933	68	2	at least 55%	PERCENT
dpc-5933	68	3	2	CARDINAL
dpc-5933	68	4	4	CARDINAL
dpc-5933	69	1	19,20	CARDINAL
dpc-5933	70	1	•	CARDINAL
dpc-5933	71	1	30%	PERCENT
dpc-5933	71	2	at least two	CARDINAL
dpc-5933	71	3	three	CARDINAL
dpc-5933	71	4	9	CARDINAL
dpc-5933	72	1	week	DATE
dpc-5933	74	1	the institutional review board	ORG
dpc-5933	74	2	yonsei university hospital	ORG
dpc-5933	75	1	4-2023-0201	CARDINAL
dpc-5933	76	1	helsinki	ORG
dpc-5933	79	1	mann-whitney	ORG
dpc-5933	80	1	fisher	ORG
dpc-5933	80	2	95%	PERCENT
dpc-5933	81	1	hiscr	GPE
dpc-5933	85	1	10.2.2	CARDINAL
dpc-5933	86	1	ten	CARDINAL
dpc-5933	86	2	48 weeks	DATE
dpc-5933	87	1	1	CARDINAL
dpc-5933	87	2	hurley stage	PERSON
dpc-5933	87	3	2	CARDINAL
dpc-5933	88	1	70%	PERCENT
dpc-5933	88	2	hurley stage ii	PERSON
dpc-5933	88	3	the remaining 30%	PERCENT
dpc-5933	88	4	hurley stage iii	PERSON
dpc-5933	89	1	40%	PERCENT
dpc-5933	89	2	anti-tnf	NORP
dpc-5933	90	1	hurley stage ii	PERSON
dpc-5933	91	1	2025;15(4):5933	CARDINAL
dpc-5933	92	1	o	DATE
dpc-5933	93	1	ge	ORG
dpc-5933	93	2	ge	ORG
dpc-5933	94	1	ea	CARDINAL
dpc-5933	95	1	fa	ORG
dpc-5933	95	2	ily hi st	PERSON
dpc-5933	95	3	2	CARDINAL
dpc-5933	96	1	ea	CARDINAL
dpc-5933	96	2	1	CARDINAL
dpc-5933	96	3	20 15	DATE
dpc-5933	97	1	24 .9	QUANTITY
dpc-5933	97	2	ng lo ba	PERSON
dpc-5933	98	1	io ti cs t a	PERSON
dpc-5933	100	1	23	CARDINAL
dpc-5933	102	1	a da lim	PERSON
dpc-5933	103	1	io ti cs t a	PERSON
dpc-5933	104	1	19 17	DATE
dpc-5933	106	1	io ti cs t	PERSON
dpc-5933	111	1	4	CARDINAL
dpc-5933	111	2	31 18 13	DATE
dpc-5933	113	1	ot ic s	PERSON
dpc-5933	114	1	io ti cs i&	PERSON
dpc-5933	116	1	28	CARDINAL
dpc-5933	116	2	io ti cs t a	PERSON
dpc-5933	119	1	5 6	CARDINAL
dpc-5933	119	2	22	CARDINAL
dpc-5933	119	3	al e pa tt er	PERSON
dpc-5933	119	4	ia	GPE
dpc-5933	119	5	io ti cs i&	PERSON
dpc-5933	121	1	22	CARDINAL
dpc-5933	121	2	20 2	TIME
dpc-5933	121	3	25 .0 8 n	QUANTITY
dpc-5933	123	1	io ti cs t	PERSON
dpc-5933	128	1	23 9 15 n o 27 .1 7	TIME
dpc-5933	128	2	io ti cs t a	PERSON
dpc-5933	130	1	54	CARDINAL
dpc-5933	131	1	3	CARDINAL
dpc-5933	131	2	ng lo ba	PERSON
dpc-5933	132	1	io ti cs t a	PERSON
dpc-5933	134	1	31 17	DATE
dpc-5933	134	2	15	CARDINAL
dpc-5933	134	3	30 .7 9	TIME
dpc-5933	134	4	io ti cs t a	PERSON
dpc-5933	136	1	vi	PERSON
dpc-5933	136	2	io na l h	FAC
dpc-5933	137	1	de ni ti s su	PERSON
dpc-5933	139	1	g lo ba l	PERSON
dpc-5933	143	1	ia	GPE
dpc-5933	144	1	al es io na	LOC
dpc-5933	145	1	ec	ORG
dpc-5933	145	2	nc	GPE
dpc-5933	145	3	e. original article	ORG
dpc-5933	146	1	2025;15(4):5933 5	CARDINAL
dpc-5933	146	2	ab le 2	ORG
dpc-5933	149	1	o	DATE
dpc-5933	149	2	ifi ed b	ORG
dpc-5933	150	1	io lo gi cs u se	PERSON
dpc-5933	152	1	m en t de la y pr io	FAC
dpc-5933	154	1	10 y ea rs	QUANTITY
dpc-5933	154	2	5	CARDINAL
dpc-5933	154	3	10	CARDINAL
dpc-5933	154	4	io lo gi cs -e xp er	PERSON
dpc-5933	154	5	nc	GPE
dpc-5933	154	6	io lo gi cs	PERSON
dpc-5933	155	1	al e 6	PERSON
dpc-5933	155	2	5	CARDINAL
dpc-5933	155	3	7 1. 43	DATE
dpc-5933	155	4	1	CARDINAL
dpc-5933	155	5	3 3. 33	DATE
dpc-5933	155	6	3	CARDINAL
dpc-5933	155	7	6	CARDINAL
dpc-5933	155	8	3	CARDINAL
dpc-5933	155	9	6	CARDINAL
dpc-5933	155	10	1	CARDINAL
dpc-5933	155	11	2 5	DATE
dpc-5933	155	12	5	CARDINAL
dpc-5933	155	13	8 3. 33	DATE
dpc-5933	155	14	al e 4	ORG
dpc-5933	155	15	2	CARDINAL
dpc-5933	155	16	2 8. 57	DATE
dpc-5933	155	17	2	CARDINAL
dpc-5933	155	18	6 6	DATE
dpc-5933	155	19	67	CARDINAL
dpc-5933	155	20	2	CARDINAL
dpc-5933	155	21	4	CARDINAL
dpc-5933	155	22	2	CARDINAL
dpc-5933	155	23	4	CARDINAL
dpc-5933	155	24	3	CARDINAL
dpc-5933	155	25	7 5	DATE
dpc-5933	155	26	1	CARDINAL
dpc-5933	155	27	67	CARDINAL
dpc-5933	155	28	ge	ORG
dpc-5933	155	29	ea	CARDINAL
dpc-5933	156	1	26 ± 4 .2	MONEY
dpc-5933	156	2	5	CARDINAL
dpc-5933	156	3	ge	ORG
dpc-5933	156	4	18 .9 ± 1 2	MONEY
dpc-5933	156	5	42	CARDINAL
dpc-5933	156	6	85	CARDINAL
dpc-5933	156	7	64	CARDINAL
dpc-5933	156	8	ea	CARDINAL
dpc-5933	157	1	io n	FAC
dpc-5933	157	2	ea	CARDINAL
dpc-5933	157	3	8	CARDINAL
dpc-5933	157	4	9 ± 5	CARDINAL
dpc-5933	157	5	84 7	DATE
dpc-5933	158	1	27 3	DATE
dpc-5933	158	2	8 ± 2	CARDINAL
dpc-5933	158	3	17	CARDINAL
dpc-5933	158	4	14 ± 2 .6 5 11 .7 5 ± 4	QUANTITY
dpc-5933	161	1	ry , n ( % ) 5 (	ORG
dpc-5933	161	2	5	CARDINAL
dpc-5933	161	3	4	CARDINAL
dpc-5933	161	4	15	CARDINAL
dpc-5933	161	5	1	CARDINAL
dpc-5933	161	6	3 3. 33	DATE
dpc-5933	161	7	3	CARDINAL
dpc-5933	161	8	6	CARDINAL
dpc-5933	161	9	2	CARDINAL
dpc-5933	161	10	4	CARDINAL
dpc-5933	161	11	1	CARDINAL
dpc-5933	161	12	2 5	DATE
dpc-5933	161	13	4	CARDINAL
dpc-5933	161	14	6 6	DATE
dpc-5933	162	1	2 25	DATE
dpc-5933	162	2	6 26	QUANTITY
dpc-5933	162	3	37	CARDINAL
dpc-5933	163	1	58 27	CARDINAL
dpc-5933	163	2	46 sm	QUANTITY
dpc-5933	163	3	4	DATE
dpc-5933	163	4	4	CARDINAL
dpc-5933	163	5	3	CARDINAL
dpc-5933	163	6	85	CARDINAL
dpc-5933	163	7	1	CARDINAL
dpc-5933	163	8	3 3. 33	DATE
dpc-5933	163	9	1	CARDINAL
dpc-5933	163	10	2	CARDINAL
dpc-5933	163	11	3	CARDINAL
dpc-5933	163	12	6	CARDINAL
dpc-5933	163	13	1	CARDINAL
dpc-5933	163	14	2 5	DATE
dpc-5933	163	15	3	CARDINAL
dpc-5933	163	16	5	CARDINAL
dpc-5933	163	17	ea	CARDINAL
dpc-5933	163	18	a da lim um	PERSON
dpc-5933	163	19	ab 4	FAC
dpc-5933	163	20	1	CARDINAL
dpc-5933	163	21	28	CARDINAL
dpc-5933	163	22	3	CARDINAL
dpc-5933	163	23	1	CARDINAL
dpc-5933	163	24	2	CARDINAL
dpc-5933	163	25	3	CARDINAL
dpc-5933	163	26	6	CARDINAL
dpc-5933	163	27	4	CARDINAL
dpc-5933	163	28	1 00	CARDINAL
dpc-5933	163	29	0	CARDINAL
dpc-5933	164	1	0	CARDINAL
dpc-5933	164	2	io ti cs	PERSON
dpc-5933	164	3	10	CARDINAL
dpc-5933	164	4	10	CARDINAL
dpc-5933	164	5	7	CARDINAL
dpc-5933	164	6	1 00	CARDINAL
dpc-5933	164	7	3	CARDINAL
dpc-5933	164	8	5	CARDINAL
dpc-5933	164	9	1 00	CARDINAL
dpc-5933	164	10	5	CARDINAL
dpc-5933	164	11	1 00	CARDINAL
dpc-5933	164	12	4	CARDINAL
dpc-5933	164	13	1 00	CARDINAL
dpc-5933	164	14	6	CARDINAL
dpc-5933	166	1	10	CARDINAL
dpc-5933	166	2	7	CARDINAL
dpc-5933	166	3	1 00	CARDINAL
dpc-5933	166	4	3	CARDINAL
dpc-5933	166	5	5	CARDINAL
dpc-5933	166	6	1 00	CARDINAL
dpc-5933	166	7	5	CARDINAL
dpc-5933	166	8	1 00	CARDINAL
dpc-5933	166	9	4	CARDINAL
dpc-5933	166	10	1 00	CARDINAL
dpc-5933	166	11	6	CARDINAL
dpc-5933	167	1	4	DATE
dpc-5933	167	2	14	CARDINAL
dpc-5933	167	3	2	CARDINAL
dpc-5933	167	4	6 6	DATE
dpc-5933	167	5	67	CARDINAL
dpc-5933	167	6	3	CARDINAL
dpc-5933	167	7	6	CARDINAL
dpc-5933	167	8	3	CARDINAL
dpc-5933	167	9	6	CARDINAL
dpc-5933	167	10	2	CARDINAL
dpc-5933	167	11	5	CARDINAL
dpc-5933	167	12	4	CARDINAL
dpc-5933	167	13	6 6	DATE
dpc-5933	167	14	7	CARDINAL
dpc-5933	168	1	ia	GPE
dpc-5933	169	1	al es io na	LOC
dpc-5933	170	1	ec	ORG
dpc-5933	170	2	nc	GPE
dpc-5933	170	3	6	CARDINAL
dpc-5933	171	1	2025;15(4):5933	CARDINAL
dpc-5933	171	2	1	CARDINAL
dpc-5933	172	1	hurley stage ii	PERSON
dpc-5933	172	2	48 weeks	DATE
dpc-5933	172	3	secukinumab administration	ORG
dpc-5933	173	1	48 weeks	DATE
dpc-5933	173	2	secukinumab administration	ORG
dpc-5933	174	1	hurley	PERSON
dpc-5933	175	1	1	CARDINAL
dpc-5933	177	1	secukinumab	GPE
dpc-5933	177	2	2	CARDINAL
dpc-5933	177	3	week 4	DATE
dpc-5933	177	4	30%	PERCENT
dpc-5933	177	5	70%	PERCENT
dpc-5933	177	6	40%	PERCENT
dpc-5933	178	1	± 27.89%	PERCENT
dpc-5933	178	2	19.4 ±	MONEY
dpc-5933	178	3	11.9 ± 12.38	CARDINAL
dpc-5933	178	4	4.69 ± 1.83	MONEY
dpc-5933	179	1	week 16	DATE
dpc-5933	179	2	70%	PERCENT
dpc-5933	179	3	ihs4-55	ORG
dpc-5933	179	4	60%	PERCENT
dpc-5933	180	1	± 10.60%	PERCENT
dpc-5933	180	2	7.6 ± 8.11	CARDINAL
dpc-5933	180	3	1.7 ± 1.54	MONEY
dpc-5933	181	1	100% to 90%	PERCENT
dpc-5933	181	2	week 8 to week 16	DATE
dpc-5933	181	3	one	CARDINAL
dpc-5933	182	1	week 48	DATE
dpc-5933	182	2	90%	PERCENT
dpc-5933	182	3	90%	PERCENT
dpc-5933	182	4	60%	PERCENT
dpc-5933	182	5	nrs30	DATE
dpc-5933	183	1	± 11.42%	PERCENT
dpc-5933	183	2	3.7 ± 5.48	CARDINAL
dpc-5933	183	3	1.99 ± 1.6	QUANTITY
dpc-5933	185	1	i&d	GPE
dpc-5933	185	2	hiscr	GPE
dpc-5933	185	3	p>0.05	ORG
dpc-5933	186	1	hurley stage ii	PERSON
dpc-5933	186	2	weeks 8	DATE
dpc-5933	186	3	0.00	CARDINAL
dpc-5933	186	4	95%	PERCENT
dpc-5933	186	5	0.00	CARDINAL
dpc-5933	186	6	0.71	CARDINAL
dpc-5933	186	7	0.00	CARDINAL
dpc-5933	186	8	95%	PERCENT
dpc-5933	186	9	0.00–0.56	PERSON
dpc-5933	186	10	3a	CARDINAL
dpc-5933	187	1	week 4	DATE
dpc-5933	187	2	p>0.05	ORG
dpc-5933	187	3	3b	CARDINAL
dpc-5933	188	1	one	CARDINAL
dpc-5933	188	2	week 16	DATE
dpc-5933	188	3	80%	PERCENT
dpc-5933	190	1	up to week 16	DATE
dpc-5933	191	1	2025;15(4):5933 7	DATE
dpc-5933	191	2	2	CARDINAL
dpc-5933	194	1	hiscr	PERSON
dpc-5933	194	2	55%	PERCENT
dpc-5933	194	3	30%	PERCENT
dpc-5933	194	4	two	CARDINAL
dpc-5933	194	5	p>0.05	ORG
dpc-5933	194	6	3c	CARDINAL
dpc-5933	195	1	100% to 80%	PERCENT
dpc-5933	195	2	p>0.05	ORG
dpc-5933	195	3	3d	CARDINAL
dpc-5933	196	1	less than 10 years	DATE
dpc-5933	196	2	55	CARDINAL
dpc-5933	196	3	week 8	DATE
dpc-5933	196	4	0.2	CARDINAL
dpc-5933	196	5	95%	PERCENT
dpc-5933	196	6	0.03622–0.6610	PERSON
dpc-5933	196	7	4a	CARDINAL
dpc-5933	197	1	week 4	DATE
dpc-5933	197	2	one	CARDINAL
dpc-5933	197	3	week 16	DATE
dpc-5933	197	4	4b	CARDINAL
dpc-5933	198	1	p>0.05	ORG
dpc-5933	198	2	4c	CARDINAL
dpc-5933	199	1	p>0.05	ORG
dpc-5933	199	2	4d	CARDINAL
dpc-5933	200	1	week 16	DATE
dpc-5933	200	2	0.25	CARDINAL
dpc-5933	200	3	95%	PERCENT
dpc-5933	200	4	0.046–0.70	DATE
dpc-5933	200	5	5a	CARDINAL
dpc-5933	201	1	week 4	DATE
dpc-5933	201	2	p>0.05	ORG
dpc-5933	201	3	5b	CARDINAL
dpc-5933	202	1	week 16	DATE
dpc-5933	202	2	80%	PERCENT
dpc-5933	203	1	p>0.05	ORG
dpc-5933	203	2	5c	CARDINAL
dpc-5933	204	1	weeks 4–8	DATE
dpc-5933	204	2	week 16	DATE
dpc-5933	204	3	5d	CARDINAL
dpc-5933	205	1	week 48	DATE
dpc-5933	205	2	66.67% to 50%	PERCENT
dpc-5933	206	1	8	CARDINAL
dpc-5933	207	1	2025;15(4):5933	CARDINAL
dpc-5933	207	2	3	CARDINAL
dpc-5933	208	1	hurley stage	PERSON
dpc-5933	209	1	hiscr	PERSON
dpc-5933	209	2	55%	PERCENT
dpc-5933	209	3	30%	PERCENT
dpc-5933	209	4	two	CARDINAL
dpc-5933	210	1	hurley stage ii	PERSON
dpc-5933	210	2	6	CARDINAL
dpc-5933	211	1	p>0.05	ORG
dpc-5933	213	1	secukinumab	PERSON
dpc-5933	213	2	3	CARDINAL
dpc-5933	214	1	the 48 weeks	DATE
dpc-5933	215	1	80 weeks	DATE
dpc-5933	216	1	48-week	DATE
dpc-5933	216	2	korean	NORP
dpc-5933	218	1	secukinumab	PERSON
dpc-5933	218	2	hiscr	GPE
dpc-5933	218	3	week 48	DATE
dpc-5933	219	1	hurley stage ii	PERSON
dpc-5933	219	2	10 years	DATE
dpc-5933	221	1	hurley stage ii	PERSON
dpc-5933	221	2	weeks 8 and 16	DATE
dpc-5933	222	1	2025;15(4):5933 9	CARDINAL
dpc-5933	222	2	4	CARDINAL
dpc-5933	224	1	hiscr	PERSON
dpc-5933	224	2	55%	PERCENT
dpc-5933	224	3	30%	PERCENT
dpc-5933	224	4	two	CARDINAL
dpc-5933	225	1	hurley	PERSON
dpc-5933	226	1	il-17a	PRODUCT
dpc-5933	228	1	21	CARDINAL
dpc-5933	229	1	10 years	DATE
dpc-5933	231	1	italian	NORP
dpc-5933	231	2	adalimumab	GPE
dpc-5933	232	1	15,22	CARDINAL
dpc-5933	235	1	ihs455	PERSON
dpc-5933	235	2	week 16	DATE
dpc-5933	235	3	two	CARDINAL
dpc-5933	235	4	week 48	DATE
dpc-5933	237	1	secukinumab	PERSON
dpc-5933	240	1	4	CARDINAL
dpc-5933	241	1	10	CARDINAL
dpc-5933	242	1	2025;15(4):5933	CARDINAL
dpc-5933	242	2	5	CARDINAL
dpc-5933	244	1	hiscr	PERSON
dpc-5933	244	2	55%	PERCENT
dpc-5933	244	3	nrs30	DATE
dpc-5933	244	4	30%	PERCENT
dpc-5933	244	5	two	CARDINAL
dpc-5933	245	1	6	CARDINAL
dpc-5933	246	1	hurley	PERSON
dpc-5933	246	2	secukinumab	GPE
dpc-5933	247	1	#	MONEY
dpc-5933	247	2	mann-whitney	PERSON
dpc-5933	250	1	korean	NORP
dpc-5933	251	1	korea	GPE
dpc-5933	251	2	six-fold	CARDINAL
dpc-5933	251	3	2003	DATE
dpc-5933	251	4	2019	DATE
dpc-5933	251	5	11.7	CARDINAL
dpc-5933	251	6	78.8	CARDINAL
dpc-5933	251	7	million	CARDINAL
dpc-5933	251	8	0.06%	PERCENT
dpc-5933	251	9	about 1:1.6	CARDINAL
dpc-5933	253	1	north american	NORP
dpc-5933	253	2	european	NORP
dpc-5933	253	3	0.1–1.0%	PERCENT
dpc-5933	253	4	roughly 3:1	CARDINAL
dpc-5933	253	5	25	CARDINAL
dpc-5933	255	1	secukinumab	PERSON
dpc-5933	256	1	9	CARDINAL
dpc-5933	257	1	9,26	CARDINAL
dpc-5933	257	2	hs	PERSON
dpc-5933	259	1	2025;15(4):5933 11	CARDINAL
dpc-5933	259	2	3	CARDINAL
dpc-5933	259	3	48 weeks	DATE
dpc-5933	259	4	secukinumab	GPE
dpc-5933	260	1	0.0	CARDINAL
dpc-5933	260	2	0.0	CARDINAL
dpc-5933	260	3	0.0	CARDINAL
dpc-5933	260	4	0	CARDINAL
dpc-5933	260	5	0.0	CARDINAL
dpc-5933	260	6	0	CARDINAL
dpc-5933	260	7	0.0	CARDINAL
dpc-5933	260	8	0	CARDINAL
dpc-5933	260	9	0.0	CARDINAL
dpc-5933	260	10	0	CARDINAL
dpc-5933	260	11	0.0	CARDINAL
dpc-5933	260	12	0.0	CARDINAL
dpc-5933	260	13	0	CARDINAL
dpc-5933	260	14	0.0	CARDINAL
dpc-5933	260	15	0.0	CARDINAL
dpc-5933	260	16	0.0	CARDINAL
dpc-5933	260	17	0	CARDINAL
dpc-5933	261	1	0.0	CARDINAL
dpc-5933	261	2	0	CARDINAL
dpc-5933	261	3	0.0	CARDINAL
dpc-5933	261	4	0	CARDINAL
dpc-5933	262	1	0.0	CARDINAL
dpc-5933	262	2	27	CARDINAL
dpc-5933	263	1	28	CARDINAL
dpc-5933	264	1	29	CARDINAL
dpc-5933	267	1	the european academy	ORG
dpc-5933	267	2	second	ORDINAL
dpc-5933	267	3	adalimumab	PERSON
dpc-5933	267	4	30	CARDINAL
dpc-5933	268	1	30	CARDINAL
dpc-5933	269	1	fda	ORG
dpc-5933	269	2	the united states	GPE
dpc-5933	269	3	adalimumab	PERSON
dpc-5933	269	4	16	CARDINAL
dpc-5933	270	1	adalimumab	PERSON
dpc-5933	270	2	first	ORDINAL
dpc-5933	271	1	korean	NORP
dpc-5933	272	1	korea	GPE
dpc-5933	272	2	asia	LOC
dpc-5933	274	1	hs	PERSON
dpc-5933	275	1	48 weeks	DATE
dpc-5933	276	1	14,15,31	CARDINAL
dpc-5933	277	1	3	CARDINAL
dpc-5933	277	2	north america	LOC
dpc-5933	277	3	europe	LOC
dpc-5933	277	4	secukinumab	GPE
dpc-5933	277	5	42–45%	PERCENT
dpc-5933	277	6	16 weeks	DATE
dpc-5933	277	7	9	CARDINAL
dpc-5933	278	1	10-16	CARDINAL
dpc-5933	279	1	15	CARDINAL
dpc-5933	280	1	secukinumab	PERSON
dpc-5933	280	2	32	CARDINAL
dpc-5933	281	1	secukinumab	PERSON
dpc-5933	281	2	korean	NORP
dpc-5933	284	1	secukinumab	PERSON
dpc-5933	285	1	secukinumab	PERSON
dpc-5933	286	1	12	CARDINAL
dpc-5933	287	1	2025;15(4):5933 10	DATE
dpc-5933	288	1	prussick l	ORG
dpc-5933	288	2	anti-interleukin-17a	NORP
dpc-5933	291	1	2019;181(3):609-611	CARDINAL
dpc-5933	292	1	doi:10.1111	ORG
dpc-5933	293	1	30801662 11	DATE
dpc-5933	294	1	secukinumab	PERSON
dpc-5933	295	1	j am	PERSON
dpc-5933	296	1	2020;82(6	CARDINAL
dpc-5933	296	2	1524-1526	CARDINAL
dpc-5933	297	1	doi:10.1016	GPE
dpc-5933	298	1	12	CARDINAL
dpc-5933	300	1	ac	ORG
dpc-5933	300	2	becherel pa	PERSON
dpc-5933	300	3	20	CARDINAL
dpc-5933	302	1	2020;34(11):e750	CARDINAL
dpc-5933	303	1	doi:10.1111	ORG
dpc-5933	304	1	13	CARDINAL
dpc-5933	305	1	italian	NORP
dpc-5933	307	1	2021;35(7):e441-e442	ORG
dpc-5933	308	1	doi:10.1111	ORG
dpc-5933	309	1	4790 14	DATE
dpc-5933	312	1	2023;13(4):1029-1038	CARDINAL
dpc-5933	313	1	15	CARDINAL
dpc-5933	314	1	ballesteros md	GPE
dpc-5933	314	2	secukinumab	PERSON
dpc-5933	316	1	2024;14(7):1875-1890	DATE
dpc-5933	318	1	martora f	PERSON
dpc-5933	318	2	cacciapuoti s	ORG
dpc-5933	318	3	secukinumab	PERSON
dpc-5933	318	4	adalimumab	PERSON
dpc-5933	318	5	52-week	DATE
dpc-5933	319	1	clin	ORG
dpc-5933	319	2	investig	GPE
dpc-5933	320	1	2024;17:159-166	CARDINAL
dpc-5933	320	2	doi:10.2147/ccid.s449367	ORG
dpc-5933	321	1	38283798 17	DATE
dpc-5933	322	1	wilson	PERSON
dpc-5933	322	2	spelman l	ORG
dpc-5933	322	3	australia	GPE
dpc-5933	323	1	plos one	ORG
dpc-5933	324	1	2018;13(7):e0200683	CARDINAL
dpc-5933	325	1	30040827 18	DATE
dpc-5933	326	1	kimball ab	PERSON
dpc-5933	326	2	sobell jm	PERSON
dpc-5933	326	3	zouboulis cc	PERSON
dpc-5933	327	1	hiscr	PERSON
dpc-5933	327	2	2	CARDINAL
dpc-5933	329	1	2016;30(6):989-94	CARDINAL
dpc-5933	330	1	doi:10.1111	ORG
dpc-5933	331	1	zouboulis cc	PERSON
dpc-5933	333	1	2017;177(5):1401-1409	DATE
dpc-5933	334	1	doi:10.1111	ORG
dpc-5933	335	1	20	CARDINAL
dpc-5933	335	2	van straalen kr	PERSON
dpc-5933	335	3	ihs4-55	ORG
dpc-5933	337	1	2023;37(2):395-401	CARDINAL
dpc-5933	338	1	doi:10.1111	ORG
dpc-5933	339	1	21	CARDINAL
dpc-5933	340	1	shishido-takahashi n	PERSON
dpc-5933	340	2	cueto	GPE
dpc-5933	341	1	novartis	ORG
dpc-5933	342	1	20024192	DATE
dpc-5933	342	2	the ministry of trade, industry & energy	ORG
dpc-5933	342	3	motie	GPE
dpc-5933	342	4	korea	GPE
dpc-5933	343	1	university of medicine	ORG
dpc-5933	343	2	ho chi	GPE
dpc-5933	343	3	the korea international cooperation agency	ORG
dpc-5933	343	4	2025	DATE
dpc-5933	344	1	2021-00020-4	DATE
dpc-5933	345	1	1	CARDINAL
dpc-5933	345	2	goldburg sr	PERSON
dpc-5933	345	3	payette mj	PERSON
dpc-5933	346	1	j am	PERSON
dpc-5933	347	1	2020;82(5):1045-1058	CARDINAL
dpc-5933	347	2	doi:10.1016	GPE
dpc-5933	349	1	2	CARDINAL
dpc-5933	349	2	zouboulis cc	PERSON
dpc-5933	349	3	bechara fg	PERSON
dpc-5933	349	4	dickinson-blok	PERSON
dpc-5933	349	5	the hs alliance working group	ORG
dpc-5933	351	1	2019;33(1):19-31	DATE
dpc-5933	352	1	doi:10.1111	ORG
dpc-5933	353	1	snyder cl	PERSON
dpc-5933	353	2	chen sx	PERSON
dpc-5933	355	1	clin	ORG
dpc-5933	355	2	investig	GPE
dpc-5933	356	1	2023;16:1833-1841	DATE
dpc-5933	358	1	pmid:37483473 4	ORG
dpc-5933	359	1	prens e	PERSON
dpc-5933	359	2	deckers i.	PERSON
dpc-5933	360	1	j am	PERSON
dpc-5933	361	1	2015;73(5	CARDINAL
dpc-5933	362	1	doi:10.1016	GPE
dpc-5933	363	1	5	CARDINAL
dpc-5933	365	1	north american	NORP
dpc-5933	365	2	the united states	GPE
dpc-5933	365	3	canadian	NORP
dpc-5933	366	1	j am	PERSON
dpc-5933	367	1	2019;81(1):91-101	CARDINAL
dpc-5933	368	1	doi:10.1016	GPE
dpc-5933	368	2	zouboulis	NORP
dpc-5933	368	3	adalimumab	PERSON
dpc-5933	369	1	rev clin immunol	PERSON
dpc-5933	370	1	2016;12(10):1015-26	CARDINAL
dpc-5933	372	1	7	CARDINAL
dpc-5933	373	1	bouwman k	PERSON
dpc-5933	374	1	adalimumab	PERSON
dpc-5933	374	2	daily	DATE
dpc-5933	376	1	2021;185(1):177	CARDINAL
dpc-5933	377	1	doi:10.1111	ORG
dpc-5933	378	1	8	CARDINAL
dpc-5933	378	2	ruggiero	PERSON
dpc-5933	379	1	martora f	PERSON
dpc-5933	379	2	picone v	ORG
dpc-5933	379	3	marano l	PERSON
dpc-5933	382	1	biomedicines10020455	PERSON
dpc-5933	383	1	9	CARDINAL
dpc-5933	383	2	kimball ab	PERSON
dpc-5933	383	3	jemec gbe	PERSON
dpc-5933	383	4	secukinumab	PERSON
dpc-5933	383	5	week 16 and week 52	DATE
dpc-5933	383	6	two	CARDINAL
dpc-5933	383	7	3	CARDINAL
dpc-5933	384	1	lancet	ORG
dpc-5933	385	1	2023;401(10378):747	CARDINAL
dpc-5933	386	1	doi:10.1016	PERSON
dpc-5933	387	1	6736(23)00 022-3	QUANTITY
dpc-5933	388	1	2025;15(4):5933	CARDINAL
dpc-5933	389	1	touhouche	PERSON
dpc-5933	390	1	j womens	PERSON
dpc-5933	391	1	2020;6(3):164-168	CARDINAL
dpc-5933	392	1	10.1016	CARDINAL
dpc-5933	393	1	32637537	DATE
dpc-5933	394	1	28	CARDINAL
dpc-5933	395	1	marzano av	PERSON
dpc-5933	395	2	micali g	PERSON
dpc-5933	397	1	2024;316(8):577	PERSON
dpc-5933	397	2	10.1007	CARDINAL
dpc-5933	398	1	39180694	DATE
dpc-5933	399	1	29	CARDINAL
dpc-5933	400	1	abu rached n	PERSON
dpc-5933	400	2	bechara fg	PERSON
dpc-5933	401	1	j clin med	PERSON
dpc-5933	402	1	2022;11(23)doi:10.3390/	CARDINAL
dpc-5933	403	1	pmid:36498816 30	ORG
dpc-5933	404	1	zouboulis cc	PERSON
dpc-5933	404	2	bechara fg	PERSON
dpc-5933	405	1	european	NORP
dpc-5933	405	2	2	CARDINAL
dpc-5933	410	1	erbagci e	PERSON
dpc-5933	410	2	bakay osk	PERSON
dpc-5933	410	3	secukinumab	PERSON
dpc-5933	412	1	2025;15(1	CARDINAL
dpc-5933	413	1	doi:10.5826	GPE
dpc-5933	413	2	dpc.1501a4915	GPE
dpc-5933	414	1	32	CARDINAL
dpc-5933	415	1	kokolakis g	PERSON
dpc-5933	416	1	42981	DATE
dpc-5933	416	2	secukinumab	PERSON
dpc-5933	416	3	week 16	DATE
dpc-5933	416	4	3	CARDINAL
dpc-5933	417	1	j am	PERSON
dpc-5933	418	1	2023;89(3):ab85	CARDINAL
dpc-5933	418	2	doi:10.1016	GPE
dpc-5933	419	1	il-17a	PRODUCT
dpc-5933	419	2	tnf	ORG
dpc-5933	421	1	2024;145(3):536-547.e7	CARDINAL
dpc-5933	422	1	doi:10.1016	GPE
dpc-5933	424	1	adalimumab	PERSON
dpc-5933	426	1	2021;184(1):133-140	CARDINAL
dpc-5933	426	2	10.1111/bjd.1898	MONEY
dpc-5933	427	1	32119111	DATE
dpc-5933	428	1	23	CARDINAL
dpc-5933	429	1	lee jh	PERSON
dpc-5933	429	2	kwon hs	PERSON
dpc-5933	429	3	jung hm	PERSON
dpc-5933	429	4	kim gm	PERSON
dpc-5933	429	5	bae jm	ORG
dpc-5933	430	1	korea	GPE
dpc-5933	432	1	2018;32(10):1784-1790	DATE
dpc-5933	433	1	doi:10.1111	ORG
dpc-5933	435	1	lee jw	PERSON
dpc-5933	435	2	heo yw	PERSON
dpc-5933	435	3	lee jh	PERSON
dpc-5933	435	4	lee s.	PERSON
dpc-5933	435	5	korea	GPE
dpc-5933	435	6	17 years	DATE
dpc-5933	437	1	2023;50(6):778786	CARDINAL
dpc-5933	441	1	clin	ORG
dpc-5933	441	2	investig	GPE
dpc-5933	442	1	2023;16:545-552	CARDINAL
dpc-5933	443	1	26	CARDINAL
dpc-5933	444	1	berg	PERSON
dpc-5933	444	2	balogh ea	PERSON
dpc-5933	444	3	ri	GPE
dpc-5933	444	4	feldman sr	PERSON
dpc-5933	447	1	2021;13(3	CARDINAL
dpc-5933	447	2	201	CARDINAL
dpc-5933	448	1	14	CARDINAL
dpc-5933	449	1	2025;15(4):5933	CARDINAL